HealthDay News — Very young children seen virtually for primary care sick visits are more likely to visit the emergency department within three days, according to a study published online December 18 ...

The B-Well 1 and B-Well 2 trials evaluated the safety, efficacy, and durability of bepirovirsen in nucleos(t)ide analogue-treated participants with CHB.

Atacicept is a recombinant fusion protein that binds to and inhibits the activity of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand).

Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

In May, the US Food and Drug Administration (FDA) approved the first at-home cervical cancer screening tool, developed by Teal Health. The wand allows patients to collect a vaginal sample themselves ...

HealthDay News — Nearly 3000 pounds of raw ground beef sold in 6 states is being recalled after testing found possible contamination with E. coli O26, federal food safety officials said.

Private equity more likely to enter states with higher autism prevalence and more generous state autism insurance mandates.

The overall age-standardized GD rates increased from 58.2 to 79.3 per 1000 live births between 2016 and 2024, with an average annual percentage change of 3.8% per year.

The sNDA for AXS-05 for Alzheimer disease agitation includes findings from four phase 3 trials showing improved behaviors and delayed relapse.

HealthDay News — Initiation of incretin receptor agonists (IRAs) is associated with lower continuous positive airway pressure (CPAP) use, hospitalization, and mortality among adults with obesity, type ...

Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.